Latest Breaking News On - Versant venture ridgeline discovery engine - Page 1 : comparemela.com

SixPeaks Bio AG Debuts With $110 Million in Funding

Next-generation obesity company with potential best- and first-in-class assets launched by Versant Ventures Emerges from stealth with $30 million in Series A financing and a strategic collaboration

Monte Rosa Therapeutics to Present at 4th Annual Targeted Protein Degradation Summit

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Monte Rosa Therapeutics Announces Addition to Russell 2000® and Russell 3000® Indexes

Investegate |RTW Venture Fund Ltd Announcements | RTW Venture Fund Ltd: Portfolio Company Update: Monte Rosa IPO

Monte Rosa Therapeutics Announces $95 Million Series C Financing to Accelerate Next-generation Protein Degradation Platform

Press release content from Business Wire. The AP news staff was not involved in its creation. Monte Rosa Therapeutics Announces $95 Million Series C Financing to Accelerate Next-generation Protein Degradation Platform March 12, 2021 GMT BOSTON (BUSINESS WIRE) Mar 12, 2021 Monte Rosa Therapeutics, a biotechnology company focused on discovering and developing precision medicines that degrade disease-causing proteins, announced today the closing of a $95 million Series C financing. The proceeds will be used to advance its lead development candidate into the clinic, accelerate pipeline growth and bolster its platform capabilities to rationally design and develop small molecule degraders (also known as molecular glues) that hijack the body’s innate ability to degrade proteins. Through this approach, Monte Rosa aims to eradicate undruggable proteins that cause or drive the progression of genomically-defined diseases intractable to standard care, including cancer.